Both serum HIV type 1 RNA levels and CD4+ lymphocyte counts predict clinical outcome in HIV type 1-infected subjects with 200 to 500 CD4+ cells per cubic millimeter

AIDS Research and Human Retroviruses

Volumn 16, Issue 7, 2000, Pages 645-653

  Kim, Soyeon ^a   Hughes, Michael D ^a   Hammer, Scott M ^b,c   Jackson, J Brooks ^d   DeGruttola, Victor ^a   Katzenstein, David A ^e  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Columbia University ^*  (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

^e STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; NUCLEOSIDE ANALOG; VIRUS RNA; ZALCITABINE; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG MONITORING; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE SUBPOPULATION; TREATMENT OUTCOME; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; CASE-CONTROL STUDIES; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 0034192134     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922200308873     Document Type: Article

References (28)

1. 1. Henrard J, Phillips JF, Muenz LR, et al.: Natural history of HIV-1 cell-free viremia. JAMA 1995;274:554-558.
2. 2. Loveday C and Hill A: Prediction of progression to AIDS with serum HIV-1 RNA and CD4 count. Lancet 1995;345:790-791.
3. 3. Mellors JW, Rinaldo CR, et al: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272:1167-1170.
4. 4. Coombs, RW, Welles SL, Hooper C, et al. : Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. J Infect Dis 1996;174:704-712.
5. 5. Katzenstein DA, Hammer SM, Hughes MD, et al.: The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-1 infected adults. N Engl J Med 1996;335:1091-1098.
6. + lymphocyte counts and the risk of progression to AIDS. N Engl J Med 1996;334:426-431.
7. + lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997;126:946-954.
8. 8. Phillips AN, Eron JJ, Bartlett JA, et al.: HIV-1 RNA levels and the development of clinical disease. AIDS 1996;10:859-865.
9. + lymphocyte counts predict both response to antiretriviral therapy and therapeutic failure. Ann Intern Med 1997;126:939-945.
10. 10. Welles SL, Jackson BL, Yen-Lieberman B, et al.: Prognostic value of plasma human immunodeficiency virus type 1 (HIV-1) RNA levels in patients with advanced HIV-1 disease and little or no prior zidovudine therapy. J Infect dis 1996;174:696-703.
11. + lymphocyte count improves assessment of antiretroviral therapeutic response. Ann Intern Med 1997;126:929-938.
12. 12. Montaner JSG, DeMasi R, and Hill AM: The effects of lamivudine treatment on HIV-1 disease progression are highly correlated with plasma HIV-1 RNA and CD4 cell count. AIDS 1998;12:F23-F28.
13. + cell counts in HIV-Infected patients. Arch Intern Med 1998;158:247-252.
14. 14. Marschner IC, Collier AC, Coombs RW, et al.: Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy. J Infect Dis 1998;177:40-47.
15. 15. Carpenter CJ, Fischl MA, Hammer SM, et al.: Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society - USA panel. JAMA 1997;277; 1962-1969.
16. 16. Hammer SM, Katzenstein DA, Hughes MD, et al.: A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. N Engl J Med 1996;335:1081-1090.
17. 17. Prentice RL: A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika 1996;73:1-11.
18. 18. Kalbfleisch JD and Lawless JF: Likelihood analysis of multi-state models for disease incidence and mortality. Stat Med 1988;7: 149-160.
19. 19. Laird NM and Ware JH: Random-effects models for longitudinal data. Biometrics 1982;38:963-974.
20. 20. Fiscus SA, Hughes MD, Lathey JL, et al.: Changes in virologic markers as predictors of CD4 cell decline and progression of disease in human immunodeficiency virus type 1-infected adults treated with nucleosides. J Infec Dis 1997;177:625-633.
21. 3. J Infect Dis 1997;177: 617-624.
22. 22. Rodriguez RJ, Dayhoff DE, Chang G, et al.: Comparison of serum and plasma viral RNA measurements in primary and chronic human immunodeficiency virus type 1 infection. J AIDS 1997;15: 49-53.
23. 23. Holodniy M, Mole L, Yen-Lieberman B, et al.: Comparative stabilities of quantitative human immunodeficiency virus RNA in plasma from samples collected in VACUTAINER CPT, VACUTAINER PPT, and standard VACUTAINER tubes. J Clin Microbiol 1995;33:1562-1566.
24. 24. Todd J, Pachl C, White R, et al.: Performance characteristic for the quantitation of plasma HIV-1 RNA using branched DNA signal amplification technology. J AIDS 1995;10:S35-S44.
25. 25. Phillips AN, Lee CA, Elford J, et al.: Serial CD4 lymphocyte counts and development of AIDS. Lancet 1991;337:389-392.
26. + lymphocytes. J Acquir Immune Defic Syndr 1995;8:496-505.
27. 27. Galai N, Muñoz A, Chen K, et al.: Tracking of markers and onset of disease among HIV-1 seroconverters. Stat Med 1993;12: 2133-2145.
28. 28. DeGruttola V, Lange N, and Dafni U: Modeling the progression of HIV infection. J Am Stat Assoc 1991;86:569-577.